BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25901794)

  • 21. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.
    Parikh C; Subrahmanyam R; Ren R
    Blood; 2006 Oct; 108(7):2349-57. PubMed ID: 16763213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The protein kinase C agonist prostratin induces differentiation of human myeloid leukemia cells and enhances cellular differentiation by chemotherapeutic agents.
    Shen X; Xiong GL; Jing Y; Xiao H; Cui Y; Zhang YF; Shan YJ; Xing S; Yang M; Liu XL; Dong B; Wang LS; Luo QL; Yu ZY; Cong YW
    Cancer Lett; 2015 Jan; 356(2 Pt B):686-96. PubMed ID: 25449427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia.
    Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Siedlecki JA
    Mol Med Rep; 2015 May; 11(5):3948-54. PubMed ID: 25585874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia.
    Cho H; Shin I; Ju E; Choi S; Hur W; Kim H; Hong E; Kim ND; Choi HG; Gray NS; Sim T
    J Med Chem; 2018 Sep; 61(18):8353-8373. PubMed ID: 30153003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed phenotype acute leukemia in a child associated with a NUP98-NSD1 fusion and NRAS p.Gly61Arg mutation.
    Ganapathi SS; Raikar SS; Yatsenko SA; Djokic M; Bukowinski A
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1372. PubMed ID: 33784031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
    You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
    Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [NRAS Gene Expression and Its Clinical Significance in Patients with Acute Myeloid Leukemia].
    Li TT; Li J; Geng YH; Zhang F; Liu L; Yang YL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):76-81. PubMed ID: 32027256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NRAS
    Pan L; Liang F; Chen X; Hao Z; Muyey DM; Chen X; Wang H
    Ann Clin Lab Sci; 2023 May; 53(3):389-397. PubMed ID: 37437942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
    Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J
    Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia.
    Sun H; Ren Y; Zhou X; Chen Q; Liu Y; Zhu C; Ruan Y; Ruan H; Tong H; Ying S; Lin P
    Technol Cancer Res Treat; 2023; 22():15330338231207765. PubMed ID: 37872685
    [No Abstract]   [Full Text] [Related]  

  • 33. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
    Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wogonoside induces depalmitoylation and translocation of PLSCR1 and N-RAS in primary acute myeloid leukaemia cells.
    Li H; Yu X; Liu X; Hu P; Shen L; Zhou Y; Zhu Y; Li Z; Hui H; Guo Q; Xu J
    J Cell Mol Med; 2018 Apr; 22(4):2117-2130. PubMed ID: 29377576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emodin enhances ATRA-induced differentiation and induces apoptosis in acute myeloid leukemia cells.
    Chen Y; Li J; Hu J; Zheng J; Zheng Z; Liu T; Lin Z; Lin M
    Int J Oncol; 2014 Nov; 45(5):2076-84. PubMed ID: 25174432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
    Riccioni R; Pasquini L; Mariani G; Saulle E; Rossini A; Diverio D; Pelosi E; Vitale A; Chierichini A; Cedrone M; Foà R; Lo Coco F; Peschle C; Testa U
    Haematologica; 2005 May; 90(5):612-24. PubMed ID: 15921376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of
    Mustafa Ali MK; Williams MT; Corley EM; AlKaabba F; Niyongere S
    Leuk Lymphoma; 2023 May; 64(5):962-971. PubMed ID: 37042657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.
    Masetti R; Bertuccio SN; Astolfi A; Chiarini F; Lonetti A; Indio V; De Luca M; Bandini J; Serravalle S; Franzoni M; Pigazzi M; Martelli AM; Basso G; Locatelli F; Pession A
    J Hematol Oncol; 2017 Jan; 10(1):26. PubMed ID: 28109323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.